MedTrace Logo

Efficacy of Oral Metformin vs Oral Doxycycline in Treating Acne Vulgaris

NCT07357337 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2026-01-22

No results posted yet for this study

Summary

The goal of the clinical trial is to learn if oral metformin works to treat moderate to severe acne vulgaris.

Investigators will compare this drug to oral doxycycline to see if this drug works to treat acne. All participants will be divided into two groups.

Group A will be given oral Metformin 500 mg to be taken twice daily, while Group B patients will be given oral Doxycycline 100 mg once daily. They will be assessed by the scoring method Total Lesion Count (TLC) and the Global Acne Grading System (GAGS) at each follow-up (i.e., at 0, 8, and 12 weeks). Efficacy will be measured by using the scoring system GAGS, TLC. The final assessment will be done at the 12th-week follow-up.

A total of 68 patients fulfilling the inclusion criteria are enrolled in the study. The efficacy of oral metformin vs oral doxycycline will be measured in all selected patients suffering from acne vulgaris by estimating improvement in the total lesion count (TLC) and the Global Acne Grading (GAGS) assessment score at each follow-up.

Conditions

  • Acne Vulgaris on the Face
  • Acne Vulgaris

Interventions

DRUG

oral metformin

Intervention group will recieve oral tablet Metformin 500mg twice daily

DRUG

Oral doxycycline

Group B will receive oral tablet Doxycycline 100mg once daily

Sponsors & Collaborators

  • Ghurki Trust and Teaching Hospital

    lead OTHER

Principal Investigators

  • Dr. Tahreem Alam Buzdar · Ghurki Trust Teaching Hospital

  • Prof. Dr. Haroon Nabi · Lahore Medical and Dental College

  • Dr Aliza Hamadani · Lahore Medical and Dental College

  • Dr. Ayesha Asad Chattha · Ghurki Trust Teaching Hospital

  • Dr. Iram Kausar · Ghurki Trust Teaching Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-15
Primary Completion
2025-08-10
Completion
2025-10-01

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07357337 on ClinicalTrials.gov